Kymera Strikes License Agreement Deals With Sanofi, Gilead
Sanofi, Gilead sign License Agreement with Kymera for protein degrader programs.
News
Stryker’s Incompass Total Ankle Wins FDA Clearance
Stryker FDA-cleared InCompass Ankle; protein degrader partnerships drive innovation.
Hereditary Angioedema Drug From CSL Gains German Backing
Hereditary angioedema therapy by CSL Behring gains positive nod in Germany.
FDA Import Ban Disrupts Olympus’ US Medical Supply
FDA import ban issued on Olympus medical devices from Japan for quality violations.
New Reimbursement Strategy Boosts Ambulatory Pay
New partnership advances reimbursement strategy for private practices.
Judge Rules ReWalk Device Is Medically Necessary for Medicare
Medicare exoskeleton coverage approved for ReWalk Personal Exoskeleton, sets key precedent.
Vor Bio and RemeGen Seal $4B Global License Agreement
Vor Bio, RemeGen sign Global License Agreement for RC98 development.
Novartis Inks $750M Flagship Pact for Cardio Innovation
Novartis makes a $750M flagship pact to address cardiovascular disease innovation.
South Korea’s Drug Pricing Reforms Reshape Market Access Landscape
South Korea’s new pharma pricing reforms reward innovation and expand access for industry.
FDA Probes Elevidys Deaths, Stirring Regulatory and Market Uncertainty
FDA investigates Elevidys deaths, raising new safety and regulatory questions for gene therapies.